Naltrekson: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan |
k Muhammad Anas Sidik memindahkan halaman Naltrexone ke Naltrekson: Judul salah eja Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
| (2 revisi perantara oleh 2 pengguna tidak ditampilkan) | |||
Baris 50:
| bioavailability = 5–60%<ref name="pmid2836152">{{cite journal |last1=Gonzalez |first1=JP |last2=Brogden |first2=RN |title=Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. |journal=Drugs |date=Maret 1988 |volume=35 |issue=3 |pages=192-213 |doi=10.2165/00003495-198835030-00002 |pmid=2836152}}</ref><ref name="pmid19537999">{{cite journal |last1=Lee |first1=MW |last2=Fujioka |first2=K |title=Naltrexone for the treatment of obesity: review and update. |journal=Expert opinion on pharmacotherapy |date=Agustus 2009 |volume=10 |issue=11 |pages=1841-5 |doi=10.1517/14656560903048959 |pmid=19537999}}</ref>
| protein_bound = 20%<ref name="pmid2836152" /><ref name="ReviaLabel" />
| metabolism = [[Liver]] (non-[[cytochrome P450|CYP450]])<ref name="SevarinoKosten2009">{{cite book | veditors = Dean RL, Bilsky EJ, Negus SS | title = Opiate Receptors and Antagonists | vauthors = Sevarino KA, Kosten TR | chapter = Naltrexone for Initiation and Maintenance of Opiate Abstinence | date = 2009 | pages =
| metabolites = [[6β-Naltrexol]], others<ref name="pmid2836152" />
| onset = 30 minutes<ref name=AHFS2017/>
Baris 109:
[[Kategori:Obat Esensial Organisasi Kesehatan Dunia]]
[[Kategori:
[[Kategori:
[[Kategori:Hepatotoksin]]
[[Kategori:4,5-Epoksimorfinan]]
[[Kategori:Keton]]
[[Kategori:Antagonis reseptor mu-opioid]]
[[Kategori:Fenol]]
<references />{{Farmasi-stub}}
| |||